Bristol-Myers Squibb Company (NYSE:BMY) is on the brink of releasing its quarterly results, with expectations running high for a mixed outcome. While positive impacts from foreign exchange rates may buoy earnings, concerns linger over potential negative effects from recent deals and challenges at the product level. Goldman Sachs analyst Asad Haider has maintained a Hold rating on the company, citing its stable stock performance despite trading at a lower multiple than peers.
The upcoming Phase-3 ADEPT-2 trial for Cobenfy in Alzheimer’s psychosis is a key focal point for investors, with the outcome likely to influence future stock movement. As a biopharmaceutical company specializing in advanced medicines for serious diseases, Bristol-Myers Squibb operates across various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience. While the company presents investment potential, the landscape of AI stocks may offer greater upside and decreased downside risk. For insights on undervalued AI stocks and their potential impact amidst current economic trends, refer to our comprehensive report.
Read more from finance.yahoo.com